New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
09:05 EDTHZNPHorizon Pharma's RAYOS 5mg reduced morning stiffness in patients with RA
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, or CAPRA- 2, trial demonstrating that patients with active rheumatoid arthritis, or RA, treated with its recently approved RAYOS 5 mg delayed-release tablets who met ACR20, DAS28 and HAQ-DI response criteria had a significantly greater reduction in morning stiffness than patients who didn't meet these criteria. Data were presented during the American College of Rheumatology, or ACR/Association of Rheumatology Health Professionals, or ARHP, Annual Scientific Meeting in Washington, D.C. Results from these analyses demonstrated that morning stiffness duration, morning stiffness severity and pain intensity upon awakening correlated with DAS28 and HAQ-DI in all treatment group analyses. There were stronger absolute correlations seen with morning stiffness severity and pain intensity upon awakening than with morning stiffness duration, whether the treatment groups were analyzed separately or together. Patients who met ACR20, DAS28 and HAQ-DI response criteria had a greater relative reduction in morning stiffness than patients who didn't meet these criteria. There were no safety concerns for RAYOS 5 mg shown in the study beyond those already established for immediate-release prednisone.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
09:09 EDTHZNPHorizon reports executive committee, commercial restructuring
Subscribe for More Information
September 23, 2014
17:02 EDTHZNPBalaji Venkataraman reports 15.6% stake in Horizon Pharma
Subscribe for More Information
07:54 EDTHZNPLeerink to hold a conference
Subscribe for More Information
September 19, 2014
16:57 EDTHZNPHorizon Pharma files automatic ordinary share shelf
10:46 EDTHZNPHorizon Pharma backs FY15 revenue view $380M-$405M, consensus $376.94M
Backs FYT15 adjusted EBITDA view $150M-$170M
10:45 EDTHZNPHorizon Pharma backs FY14 revenue view $270M-$280M, consensus $277.56M
Subscribe for More Information
September 18, 2014
19:50 EDTHZNPHorizon Pharma trading halted, pending news
Subscribe for More Information
09:19 EDTHZNPHorizon Pharma announces holder approval of Vidara acquisition
Subscribe for More Information
September 16, 2014
06:21 EDTHZNPHorizon Pharma to host special shareholder meeting
Special shareholder meeting to consider and seek shareholder approval of the acquisition of Vidara Therapeutics, will be held in Deerfield, IL on September 18 at 9 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use